Protagenic Therapeutics

Protagenic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for stress-related neuropsychiatric and mood disorders, including depression, anxiety, and post-traumatic stress disorder (PTSD). Its lead compound, PT00114, is a synthetic peptide modeled after the endogenous brain hormone Teneurin Carboxy-terminal Associated Peptide (TCAP), which modulates stress response by reducing overactive signaling and circulating cortisol levels. This novel mechanism addresses the cellular stress feedback loop implicated in neuropsychiatric conditions. The company also has a portfolio of earlier-stage neuropeptides in preclinical development targeting the TCAP pathway. Established in 1994 and based in New York, Protagenic Therapeutics aims to provide first-in-class treatments that restore healthy brain function by regulating stress response, addressing areas of significant unmet medical need in mental health.